Matt Sagan, Founder, Managing Partner, and CEO of MoD Partners, as well as Co-Founder, Vice President, Chief Growth and Financial Officer at VAXiCAN, shared a post by OncoDaily Breast, adding:
“HER2 positive breast cancer success story is not finished yet
New treatment options will be widely available as well as we need to focus more on brain metastasis
Cancer Vaccines can become a strong option next to mAb ADC inhibitors and CarT.”
Quoting OncoDaily Breast‘s post:
“HER2-positive breast cancer was once one of the most feared subtypes in breast oncology.
Aggressive biology.
Higher recurrence risk.
Poorer prognosis.
Today, that same biology has become one of the greatest success stories of precision oncology.
Over the past two decades, HER2-positive breast cancer has moved from a diagnosis associated with fear to a model of what targeted therapy can achieve.
We have seen the field evolve from trastuzumab to dual HER2 blockade, from T-DM1 to trastuzumab deruxtecan, and from standard systemic control to increasingly sophisticated strategies that ask a very different question:
Not only, “How do we treat more?”
But also, “How do we treat smarter?”
In early HER2-positive breast cancer, de-escalation is now a real scientific conversation. Anthracycline-free approaches, chemotherapy-minimized regimens, and response-adapted strategies are changing how we think about treatment intensity.
In metastatic disease, some patients are living longer and better than many would have imagined years ago.
But the story is not finished.
Brain metastases remain one of the most important unmet needs in HER2-positive breast cancer. Even when extracranial disease is well controlled, the CNS can remain vulnerable.
The next frontier is clear:
- Better CNS control
- Better treatment selection
- Smarter sequencing
- Better quality of life
- And one day, prevention of brain metastases altogether
HER2-positive breast cancer once represented fear.
Today, it represents one of oncology’s clearest stories of hope.
Read more on OncoDaily Breast.”
Other articles featuring Matt Sagan.